Company: PMVP
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001140361-25-015610
Chunk: 23

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 23
---
isters our equity compensation plans. |

The compensation committee has the right, in its sole discretion, to retain or obtain the advice of compensation consultants, independent legal counsel and other advisers. The compensation committee operates under a written charter that satisfies the applicable rules of the SEC and Nasdaq listing rules. Our compensation committee’s written charter may be located on our website at ir.pmvpharma.com. The compensation committee met five times in fiscal year 2024. Nominating and Corporate Governance Committee The nominating and corporate governance committee consists of Dr. Baum, Dr. Gallagher and Dr. Heyman, each of whom meets the requirements for independence under current Nasdaq listing standards and SEC rules and regulations. Dr. Baum is the chairperson of the nominating and corporate governance committee. The nominating and corporate governance committee oversees and assists our board of directors in reviewing and recommending nominees for election as directors. Among other matters, our nominating and corporate governance committee also:

| • | identifies, evaluates and makes recommendations to our board of directors regarding nominees for election to our board of directors and its committees; |

| • | considers and makes recommendations to our board of directors regarding the composition of our board of directors and its committees; |

| • | reviews and makes recommendations to our board of directors with respect to management succession planning; |

| • | reviews developments in corporate governance practices; |

| • | evaluates the adequacy of our corporate governance practices and reporting, including providing oversight for our sustainability related to Environmental, Social and Governance programs, reporting and policy initiatives; and |

| • | evaluates the performance of our board of directors and individual members. |

Our nominating and corporate governance committee operates under a written charter that satisfies applicable rules of the SEC and Nasdaq listing rules. Our nominating and corporate governance committee’s written charter may be located on our website at ir.pmvpharma.com. The nominating and corporate governance committee met three times in fiscal year 2024. Identifying and Evaluating Director Nominees Our board of directors has delegated to the nominating and corporate governance committee the responsibility of identifying individuals qualified to become members of the board of directors and recommending to the board of directors nominees to fill vacancies and newly created directorships and the nominees to stand for election as directors. If the nominating and corporate governance committee determines that an additional or replacement director is required, it may take such measures that it considers appropriate in connection with its evaluation of a director candidate, including candidate interviews, inquiry of the person or persons making the recommendation or nomination,